贝瑞基因(000710) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥238,222,453.79, representing a decrease of 12.06% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥25,321,174.92, a significant decline of 2,355.45% year-on-year[5]. - The basic earnings per share for the period was -¥0.0716, reflecting a decrease of 2,337.50% compared to the previous year[5]. - Total operating revenue decreased to ¥685,656,794.86 from ¥822,664,528.62, representing a decline of approximately 16.67% year-over-year[21]. - Net profit for the period was a loss of ¥50,421,996.34, compared to a profit of ¥13,944,517.00 in the previous period, indicating a significant downturn[22]. - The company's operating profit turned negative at ¥-42,124,510.87, compared to a positive operating profit of ¥27,346,425.46 in the prior year[22]. - Basic and diluted earnings per share were both ¥-0.1487, a decrease from ¥0.0294 in the previous period[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,343,710,762.08, down 1.72% from the end of the previous year[5]. - Total current assets decreased from 1,439,086,278.92 CNY to 1,298,059,150.34 CNY, a reduction of approximately 9.8%[17]. - Cash and cash equivalents decreased from 383,071,864.35 CNY to 309,746,339.92 CNY, a decline of about 19.2%[17]. - Total non-current assets increased from 945,637,715.14 CNY to 1,045,651,611.74 CNY, an increase of about 10.6%[18]. - Total liabilities increased to ¥694,434,225.54 from ¥669,562,176.39, marking an increase of about 3.00%[22]. - Total equity attributable to shareholders decreased to ¥1,619,622,588.29 from ¥1,679,476,362.94, a decline of approximately 3.57%[22]. Cash Flow - The cash flow from operating activities showed a net outflow of -¥24,582,830.89, a decline of 207.34% compared to the same period last year[11]. - Cash flow from operating activities was ¥759,679,533.20, down from ¥821,350,091.16, reflecting a decline of approximately 7.51% year-over-year[25]. - Net cash flow from operating activities was -$24.58 million, a decrease from $22.90 million in the previous period[26]. - Total cash inflow from investment activities was $15.56 million, down from $309.50 million[26]. - Cash outflow from investment activities totaled $69.82 million, compared to $247.63 million previously[26]. - Net cash flow from financing activities was $23.14 million, a significant improvement from -$198.51 million[27]. - The ending cash and cash equivalents balance was $300.55 million, compared to $201.54 million at the end of the previous period[27]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 64,711[13]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.45% of shares, totaling 44,002,000 shares, which are frozen and pledged[13]. Research and Development - Research and development expenses increased by 34.67% to ¥78,716,866.22, indicating a focus on innovation[10]. - The company reported a significant increase in research and development expenses to ¥78,716,866.22 from ¥58,453,739.70, an increase of about 34.67% year-over-year[22]. - The company is focusing on the development of AI-driven genetic testing technology through its collaboration with the new joint venture[15]. Investments and Joint Ventures - Investment income rose by 168.40% to ¥4,650,790.35, attributed to increased returns from joint ventures[10]. - The company recorded a fair value change gain of ¥2,203,689.24, a turnaround from a loss in the previous year[10]. - The company has established a joint venture, Henan Yuanmeng Kangtong Gene Technology Co., Ltd., to provide integrated testing services for genetic diseases in newborns and children[15]. Other Financial Metrics - Total operating costs decreased to ¥713,217,299.16 from ¥765,979,082.06, a reduction of about 6.89% year-over-year[22]. - Deferred income tax liabilities rose to ¥25,796,262.41 from ¥24,895,474.67, an increase of approximately 3.63%[22]. - Short-term borrowings increased from 113,415,839.27 CNY to 152,448,975.65 CNY, an increase of about 34.4%[18]. - The company experienced a 215.93% increase in lease liabilities, totaling ¥136,604,120.59, due to new leasing agreements[10]. - The company reported a significant increase in receivables, with a 354.19% rise in notes receivable to ¥11,750,786.08[10].